Sugi Predict

Sugi Predict / Compounds / Prunasin

Prunasin

Prunasin

SCHEMBL377612

N#C[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYNJ2 O15056 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ ABL1 P00519 1/20 0.50
▸ ALPL P05186 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ ALPI P09923 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ ALPG P10696 1/20 0.50
▸ PABPC1 P11940 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ GALK1 P51570 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ CASP6 P55212 1/20 0.50
▸ MCL1 Q07820 1/20 0.50
▸ RIN1 Q13671 1/20 0.50
▸ EIF4H Q15056 1/20 0.50
▸ CD209 Q9NNX6 2/20 0.48
▸ TYR P14679 1/20 0.44
▸ ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Prunasin SCHEMBL440675 1.00 SYNJ2 (0.50) SYNJ2MAPTKDM4EABL1ALPL
Prunasin SCHEMBL30671478 1.00 SYNJ2 (0.50) SYNJ2MAPTKDM4EABL1ALPL
Prunasin SCHEMBL4925774 1.00 SYNJ2 (0.50) SYNJ2MAPTKDM4EABL1ALPL
Prunasin SCHEMBL16147925 1.00 SYNJ2 (0.50) SYNJ2MAPTKDM4EABL1ALPL
Vitamin B17 SCHEMBL20644200 0.93 SYNJ2 (0.45) SYNJ2MAPTKDM4EABL1ALPL
Vitamin B17 SCHEMBL20644202 0.93 SYNJ2 (0.45) SYNJ2MAPTKDM4EABL1ALPL
Vitamin B17 SCHEMBL131407 0.93 SYNJ2 (0.45) SYNJ2MAPTKDM4EABL1ALPL
Vitamin B17 SCHEMBL22227478 0.93 SYNJ2 (0.45) SYNJ2MAPTKDM4EABL1ALPL
Vitamin B17 SCHEMBL22227477 0.93 SYNJ2 (0.45) SYNJ2MAPTKDM4EABL1ALPL
Vitamin B17 SCHEMBL16148248 0.93 SYNJ2 (0.45) SYNJ2MAPTKDM4EABL1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4649136-A1 GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF NITROGEN AND CARBON-CONTAINING COMPOUNDS Fertis India Pvt Ltd (IN) 2025-11-19 — — EP claimed
US-20240365823-A1 PROCESS FOR PRODUCING PLANT SEED MATERIAL HAVING A REDUCED CONTENT OF CYANOGENIC COMPOUNDS KERN TEC GMBH (AT) 2024-11-07 — — US claimed
WO-2024121871-A1 GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF NITROGEN AND CARBON-CONTAINING COMPOUNDS FERTIS INDIA PVT. LTD. (IN) 2024-06-13 — — WO claimed
EP-4362700-A1 PROCESS FOR PRODUCING PLANT SEED MATERIAL HAVING A REDUCED CONTENT OF CYANOGENIC COMPOUNDS Kern Tec GmbH (AT) 2024-05-08 — — EP claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 — — CN claimed
CN-113679731-B Application of prunasin in preparation of medicine for treating fatty liver disease and hepatic fibrosis 上海中医药大学附属曙光医院 2023-03-31 — — CN claimed
CN-115851597-A Method for differentiating induced pluripotent stem cells into neural stem cells and application 海南苏生生物科技有限公司 2023-03-28 — — CN claimed
CN-113341000-B Method for determining concentration of sodium danshensu and prunasin in dog plasma 上海黄海制药有限责任公司 2023-02-10 — — CN claimed
WO-2023275291-A1 PROCESS FOR PRODUCING PLANT SEED MATERIAL HAVING A REDUCED CONTENT OF CYANOGENIC COMPOUNDS KERN TEC GMBH (AT) 2023-01-05 — — WO claimed
CN-114624349-B Method for analyzing traditional Chinese medicinal materials in lung-heat clearing and toxin expelling decoction formula 中国科学院大连化学物理研究所 2022-12-27 — — CN claimed
CN-102791855-A Whole cell biocatalyst ZYRUS BETEILIGUNGSGMBH & CO PATENTE I KG 2012-11-21 — — CN claimed
EP-2501807-A2 WHOLE CELL BIOCATALYST ZYRUS Beteiligungsgesellschaft mbH & Co. Patente I KG (DE) 2012-09-26 — — EP claimed
WO-2012094636-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — WO claimed
EP-2338987-A1 Whole cell biocatalyst ZYRUS Beteiligungsgesellschaft mbH & Co. Patente I KG (DE) 2011-06-29 — — EP claimed
WO-2011057820-A2 WHOLE CELL BIOCATALYST ZYRUS BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE I KG (DE) 2011-05-19 — — WO claimed
US-20080027023-A1 Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives GLUCOGENE MEDICAL HFM AB (SE) 2008-01-31 — — US claimed
EP-1765363-A2 NEW COMPOSITIONS GLUCOGENE MEDICAL HFM AB (SE) 2007-03-28 — — EP claimed
CN-1742954-A Urotoxin clearing preparation-Niaoduqing HUA WEIMING (CN) 2006-03-08 — — CN claimed
WO-2006006933-A2 ANTIPROLIFERATIVE COMPOSITIONS COMPRISING ARYL SUBSTITUTED XYLOPYRANOSIDE DERIVATIVES GLUCOGENE MEDICAL HFM AB (SE) 2006-01-19 — — WO claimed
CN-1555413-A Vascular tissue preferred promoters �ȷ�߼����ֹ��ʹɷ����޹�˾ 2004-12-15 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027023-A1 Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives UGGT1, B3GAT3, MKI67 SYNJ2 2703/4885MAPT 4677/4885KDM4E 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.